Twist Bioscience Corporation (NASDAQ:TWST) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Twist Bioscience Corporation (NASDAQ:TWST) have been assigned a consensus recommendation of “Moderate Buy” from the nine brokerages that are presently covering the stock, Marketbeat.com reports. Two research analysts have rated the stock with a sell recommendation and seven have given a buy recommendation to the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $45.8750.

Several brokerages have commented on TWST. Robert W. Baird set a $50.00 target price on shares of Twist Bioscience in a report on Tuesday, February 3rd. Evercore boosted their price target on shares of Twist Bioscience from $42.00 to $52.00 and gave the company an “outperform” rating in a report on Tuesday, February 3rd. TD Cowen reissued a “buy” rating on shares of Twist Bioscience in a research note on Thursday, January 8th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Twist Bioscience in a report on Monday, December 29th. Finally, Barclays upped their price target on Twist Bioscience from $39.00 to $50.00 and gave the company an “overweight” rating in a research report on Tuesday, February 3rd.

Insider Buying and Selling

In related news, insider Dennis Cho sold 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, February 11th. The shares were sold at an average price of $49.93, for a total transaction of $249,650.00. Following the transaction, the insider directly owned 138,581 shares of the company’s stock, valued at approximately $6,919,349.33. The trade was a 3.48% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Jan Johannessen sold 2,200 shares of the company’s stock in a transaction that occurred on Friday, February 6th. The shares were sold at an average price of $47.91, for a total transaction of $105,402.00. Following the completion of the transaction, the director owned 17,754 shares in the company, valued at approximately $850,594.14. This represents a 11.03% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 36,609 shares of company stock worth $1,665,151 over the last ninety days. 3.08% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Twist Bioscience

A number of institutional investors have recently modified their holdings of TWST. Quarry LP purchased a new position in shares of Twist Bioscience during the 3rd quarter valued at $28,000. Smartleaf Asset Management LLC raised its holdings in shares of Twist Bioscience by 70.6% during the third quarter. Smartleaf Asset Management LLC now owns 1,068 shares of the company’s stock worth $29,000 after acquiring an additional 442 shares in the last quarter. Strategic Advocates LLC boosted its position in Twist Bioscience by 562.7% during the fourth quarter. Strategic Advocates LLC now owns 1,067 shares of the company’s stock valued at $34,000 after purchasing an additional 906 shares during the last quarter. SBI Securities Co. Ltd. boosted its position in Twist Bioscience by 68.9% during the fourth quarter. SBI Securities Co. Ltd. now owns 1,400 shares of the company’s stock valued at $44,000 after purchasing an additional 571 shares during the last quarter. Finally, National Bank of Canada FI purchased a new position in Twist Bioscience in the third quarter valued at about $46,000.

Twist Bioscience Trading Down 3.5%

Shares of NASDAQ TWST opened at $46.94 on Monday. Twist Bioscience has a 12 month low of $23.30 and a 12 month high of $57.88. The company has a market cap of $2.88 billion, a price-to-earnings ratio of -36.67 and a beta of 2.23. The company has a quick ratio of 3.37, a current ratio of 3.78 and a debt-to-equity ratio of 0.03. The business has a fifty day simple moving average of $43.61 and a 200-day simple moving average of $34.65.

Twist Bioscience (NASDAQ:TWST) last issued its quarterly earnings results on Monday, February 2nd. The company reported ($0.50) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.02). The company had revenue of $103.70 million during the quarter, compared to analysts’ expectations of $100.32 million. Twist Bioscience had a negative return on equity of 27.16% and a negative net margin of 19.56%.Twist Bioscience’s quarterly revenue was up 16.9% on a year-over-year basis. Sell-side analysts predict that Twist Bioscience will post -2.12 EPS for the current year.

About Twist Bioscience

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.